Mechanically, ARID1A deficiency causes the epigenetic activation of Ang2; therefore, antiangiogenic therapies against Ang2 in ARID1A-deficient HCC may have good therapeutic effects [156]. This evidence concerns the gene ARID1A and hepatocellular carcinoma.